{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:26:01Z","timestamp":1788823561236,"version":"build-2803163510"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 CA213139"],"award-info":[{"award-number":["R21 CA213139"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["BC132124"],"award-info":[{"award-number":["BC132124"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["LC160212"],"award-info":[{"award-number":["LC160212"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001755","name":"Mesothelioma Applied Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001755","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Baker Street Foundation"},{"DOI":"10.13039\/100016228","name":"Derfner Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016228","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Joanne and John DallePezze Foundation"},{"name":"Mr. William H. Goodwin and Alice Goodwin"},{"DOI":"10.13039\/100004436","name":"Commonwealth Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Experimental Therapeutics Center"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jtho.2017.10.001","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T01:17:01Z","timestamp":1509067021000},"page":"16-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies"],"prefix":"10.1016","volume":"13","author":[{"given":"Stefan","family":"Kiesgen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Chicaybam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin K.","family":"Chintala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1699-2046","authenticated-orcid":false,"given":"Prasad S.","family":"Adusumilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2017.10.001_bib1","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/00000441-189305000-00001","article-title":"The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases","volume":"105","author":"Coley","year":"1893","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jtho.2017.10.001_bib2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0163-7258(94)90023-X","article-title":"Coley's toxins, tumor necrosis factor and cancer research: a historical perspective","volume":"64","author":"Wiemann","year":"1994","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jtho.2017.10.001_bib3","first-page":"769","article-title":"Immunity to methylcholanthrene-induced sarcomas","volume":"18","author":"Prehn","year":"1957","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2017.10.001_bib4","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(67)92837-1","article-title":"Immunological aspects of malignant disease","volume":"1","author":"Burnet","year":"1967","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2017.10.001_bib5","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1084\/jem.184.5.1781","article-title":"Decreased tumor surveillance in perforin-deficient mice","volume":"184","author":"van den Broek","year":"1996","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jtho.2017.10.001_bib6","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2017.10.001_bib7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases\u2014elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jtho.2017.10.001_bib8","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","article-title":"Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2","volume":"86","author":"Rosenberg","year":"1994","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2017.10.001_bib9","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting\u00a0chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.10.001_bib10","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jtho.2017.10.001_bib11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtho.2017.10.001_bib12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ni.3682","article-title":"'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations","volume":"18","author":"Tran","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jtho.2017.10.001_bib13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","article-title":"The urgent need to recover MHC class I in cancers for effective immunotherapy","volume":"39","author":"Garrido","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jtho.2017.10.001_bib14","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/leu.2016.373","article-title":"Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms tumor 1 antigen","volume":"31","author":"Rafiq","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jtho.2017.10.001_bib15","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2017.10.001_bib16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2017.10.001_bib17","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1182\/blood.V128.22.650.650","article-title":"Minimal residual disease negative complete remissions following anti-CD22 chimeric antigen receptor (CAR) in children and young adults with relapsed\/refractory acute lymphoblastic leukemia (ALL)","volume":"128","author":"Shah","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtho.2017.10.001_bib18","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.jtho.2017.10.001_bib19","doi-asserted-by":"crossref","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2017.10.001_bib20","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.jtho.2017.10.001_bib21","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/MOH.0000000000000181","article-title":"Challenges and opportunities of allogeneic donor-derived CAR T cells","volume":"22","author":"Yang","year":"2015","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jtho.2017.10.001_bib22","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.2012.45.2052","article-title":"Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor beta2 (IL-12Rbeta2), IL-7R, and stromal FoxP3\/CD3 ratio are independent predictors of recurrence","volume":"31","author":"Suzuki","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.10.001_bib23","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1097\/JTO.0000000000000617","article-title":"Prognostic impact of immune microenvironment in lung squamous cell carcinoma: tumor-infiltrating CD10+ neutrophil\/CD20+ lymphocyte ratio as an independent prognostic factor","volume":"10","author":"Kadota","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.10.001_bib24","doi-asserted-by":"crossref","first-page":"e1009285","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and\u00a0stromal immune microenvironment in malignant pleural\u00a0mesothelioma: a comprehensive analysis reveals\u00a0prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2017.10.001_bib25","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/JTO.0000000000000551","article-title":"Non-small-cell lung cancer: role of the immune\u00a0system and potential for immunotherapy","volume":"10","author":"Carbone","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.10.001_bib26","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtho.2017.10.001_bib27","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified t cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.10.001_bib28","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s11427-016-5023-8","article-title":"Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed\/refractory non-small cell lung cancer","volume":"59","author":"Feng","year":"2016","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.jtho.2017.10.001_bib29","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2017.10.001_bib30","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2017.10.001_bib31","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","article-title":"Mesothelin\u00a0overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma","volume":"20","author":"Kachala","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2017.10.001_bib32","doi-asserted-by":"crossref","first-page":"e114900","DOI":"10.1371\/journal.pone.0114900","article-title":"Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival","volume":"9","author":"Tozbikian","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2017.10.001_bib33","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1158\/1055-9965.EPI-11-0993","article-title":"Tissue and serum\u00a0mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma","volume":"21","author":"Rizk","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jtho.2017.10.001_bib34","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.lungcan.2016.09.015","article-title":"Expression of mesothelin in thymic carcinoma and its potential therapeutic significance","volume":"101","author":"Thomas","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2017.10.001_bib35","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtho.2017.10.001_bib36","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2017.10.001_bib37","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.18632\/oncotarget.6595","article-title":"Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"issue":"suppl 3","key":"10.1016\/j.jtho.2017.10.001_bib38","doi-asserted-by":"crossref","first-page":"S356","DOI":"10.1245\/s10434-014-3579-8","article-title":"EpCAM, a potential therapeutic target for esophageal squamous cell carcinoma","volume":"21","author":"Matsuda","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jtho.2017.10.001_bib39","doi-asserted-by":"crossref","first-page":"e1284722","DOI":"10.1080\/2162402X.2017.1284722","article-title":"PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells","volume":"6","author":"Wei","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2017.10.001_bib40","doi-asserted-by":"crossref","first-page":"e2286","DOI":"10.1097\/MD.0000000000002286","article-title":"Prognostic significance of mucin antigen MUC1 in various human epithelial cancers: a meta-analysis","volume":"94","author":"Xu","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jtho.2017.10.001_bib41","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","article-title":"The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jtho.2017.10.001_bib42","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtho.2017.10.001_bib43","doi-asserted-by":"crossref","first-page":"36447","DOI":"10.1038\/srep36447","article-title":"ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma","volume":"6","author":"Zheng","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2017.10.001_bib44","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1479-5876-11-187","article-title":"Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells","volume":"11","author":"Schuberth","year":"2013","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.jtho.2017.10.001_bib45","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/0008-5472.CAN-14-3041","article-title":"Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells","volume":"75","author":"Lo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2017.10.001_bib46","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1084\/jem.20130110","article-title":"Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia","volume":"210","author":"Tran","year":"2013","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jtho.2017.10.001_bib47","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2017.10.001_bib48","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of\u00a0cancer treatment: immunomodulation, CARs and combination\u00a0immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2017.10.001_bib49","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and\u00a0CD123 targeting prevents antigen-loss relapses after\u00a0CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtho.2017.10.001_bib50","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1586\/14760584.2015.982101","article-title":"Regulation of cytotoxic T-Lymphocyte trafficking to tumors by chemoattractants: implications for immunotherapy","volume":"14","author":"Sharma","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jtho.2017.10.001_bib51","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2017.10.001_bib52","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-targeted CARs: friving T Cells to solid tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2017.10.001_bib53","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.cell.2015.08.012","article-title":"Phosphoenolpyruvate Is a metabolic checkpoint of anti-tumor T cell responses","volume":"162","author":"Ho","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2017.10.001_bib54","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","article-title":"Inhibitory effect of tumor cell-derived lactic acid on human T cells","volume":"109","author":"Fischer","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtho.2017.10.001_bib55","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","article-title":"L-Arginine modulates\u00a0T cell metabolism and enhances survival and anti-tumor activity","volume":"167","author":"Geiger","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2017.10.001_bib56","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.lungcan.2013.02.017","article-title":"Tumor-associated macrophages in thoracic malignancies","volume":"80","author":"Lievense","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2017.10.001_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2016.06.021","article-title":"Pleural effusion of patients with malignant mesothelioma induces macrophage-mediated T cell suppression","author":"Lievense","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.10.001_bib58","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.jtho.2016.06.022","article-title":"Pleural effusions from patients with mesothelioma induce recruitment of monocytes and their differentiation into M2 macrophages","volume":"11","author":"Chene","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.10.001_bib59","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/PPO.0000000000000006","article-title":"Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer","volume":"19","author":"Albeituni","year":"2013","journal-title":"Cancer J"},{"key":"10.1016\/j.jtho.2017.10.001_bib60","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res"},{"key":"10.1016\/j.jtho.2017.10.001_bib61","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/JTO.0b013e3181ce3afd","article-title":"TGF-beta signaling and the role of inhibitory Smads in non-small cell lung cancer","volume":"5","author":"Jeon","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.10.001_bib62","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1158\/1078-0432.CCR-03-0611","article-title":"Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity","volume":"10","author":"Suzuki","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2017.10.001_bib63","first-page":"1273","article-title":"Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy","volume":"59","author":"Won","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2017.10.001_bib64","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ni.1607","article-title":"A\u00a0critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells","volume":"9","author":"Liu","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jtho.2017.10.001_bib65","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","article-title":"TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance","volume":"8","author":"Thomas","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2017.10.001_bib66","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1182\/blood.V99.9.3179","article-title":"Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity","volume":"99","author":"Bollard","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtho.2017.10.001_bib67","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtho.2017.10.001_bib68","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A\u00a0chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2017.10.001_bib69","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nbt0817-691","article-title":"First approval in sight for Novartis' CAR-T therapy after panel vote","volume":"35","author":"Sheridan","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtho.2017.10.001_bib70","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","article-title":"A\u00a0phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer","volume":"13","author":"Koneru","year":"2015","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.jtho.2017.10.001_bib71","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"}],"updated-by":[{"DOI":"10.1016\/j.jtho.2018.01.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000}}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086417327879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086417327879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T18:30:00Z","timestamp":1690050600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086417327879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1556086417327879"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2017.10.001","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jtho.2018.01.001","asserted-by":"object"}]},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2017.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}